Different Genetic Features Associated With Hepatic Carcinogenesis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01247506|
Recruitment Status : Unknown
Verified November 2010 by National Taiwan University Hospital.
Recruitment status was: Recruiting
First Posted : November 24, 2010
Last Update Posted : November 24, 2010
|Condition or disease|
Hepatocellular carcinoma (HCC) is a leading cause of cancer deaths in Taiwan. HCC normally develops as a consequence of underlying liver disease and is most often associated with cirrhosis. Surgical resection and liver transplantation are current best curative options to treat HCC. However, recurrence or metastasis is quite common in patients who have had a resection and survival rate is 30% to 40% at 5 years postoperatively.
MicroRNAs, small non-coding RNA, act as endogenous RNA interference by post-transcription regulation. Recent studies suggest that microRNAs may act as tumor suppressors or oncogenes and altered microRNA expression levels may play an important role in the cancer initiation and progression. Several studies, including ourselves, have shown that specific microRNAs are aberrantly expressed in malignant HCC tissues compared to normal counterpart. Although many microRNA profiling studies were done to diagnose hepatocarcinogenesis, data about prognostic significances for postsurgical survival are very limited. The main point of this study is to develop a predictive signature for postsurgical survival in HCC patients.
|Study Type :||Observational|
|Estimated Enrollment :||160 participants|
|Observational Model:||Case Control|
|Official Title:||Identification of Survival-related microRNAs in Hepatocellular Carcinoma|
|Study Start Date :||February 2010|
|Estimated Primary Completion Date :||July 2012|
|Estimated Study Completion Date :||July 2012|
tumor tissues of HCC patients
paired nontumor tissues of HCC patients
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01247506
|Contact: Tzu-Min Hung, PhD||886-2-23123456 ext email@example.com|
|National Taiwan University Hospital||Recruiting|
|Principal Investigator: Cheng-Maw HO|
|Study Chair:||Po-Huang Lee, PhD||National Taiwan University Hospital|